While IL2 has been used to therapeutically stimulate the immune system and has recently been shown to synergize with STING agonists and checkpoint inhibitors in mouse models of primary mammary carcinoma (71), the role of IL2 as a proinflammatory or anti-inflammatory mediator is determined by the immunologic composition of the tissue of interest (72). Here, STING1 is linked to breast carcinoma.